

Hypo- versus normofractionated radiation therapy of early breast cancer in the randomized DBCG HYPO trial

BV Offeresen¹, HM Nielsen¹, EH Jacobsen², MH Nielsen³, M Krause⁴, L Stenbygaard⁵, I Mjaaland⁶, A Schreiber⁷, UM Kasti⁸, M Jensen⁹, J Overgaard¹⁰

¹Dept Oncol, Aarhus University Hospital, Aarhus, Denmark, ²Dept Oncol, Lillebaelt Hospital, Vejle, Denmark, ³Dept Oncol, Odense University Hospital, Odense, Denmark, ⁴Clinic for Radiother and Oncol, University Clinic Carl Gustav Carus, Technical University Dresden, Dresden, Germany, ⁵Dept Oncol, Aalborg University Hospital, Aalborg, Denmark, ⁶Dept of Oncol, Stavanger University Hospital, Stavanger, Norway, ⁷Dept Oncol, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany, ⁸Dept Oncol, Kristiansand, Norway, ⁹Danish Breast Cancer Group, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ¹⁰Dept of Expt Clin Oncol, Aarhus University Hospital, Aarhus, Denmark



No conflicts of interest



Background DBCG HYPO Trial

Moderate hypofractionation 36-42 Gy / 12 fr DBCG standard before 1982



RT 1980
Photo 2010,
30 yr follow up

Besvär efter åtta år

En av de drabbade, Marianne Mosserud, berättade för Aktuellt om hur besvären i armen som började åtta år efter bröstoperationen nu gör henne allt mer handikappad.




Marianne Mosserud

-Jag kan ju inte lyfta ett papper ens. Jag kan inte knipa ihop med fingrarna. Jag kan inte.

Är det nånting som jag ska bära, så får jag ta det i munnen.

Och det är ju svårt med tunga saker...

Ett papper kan man ju ta, nån filt eller så, berättade Marianne.



~3.3 mio Euro

Komiteens tilråding

Komiteen viser for øvrig til proposisjonen og det som står foran, og råar Stortinget til å gjøre følgende

vedtak:

I statsbudsjettet for 1998 gjøres følgende endring:

Kap. 739	Andre utgifter		
	73 (ny)	Erstatning for stråleskader, kan overføres	
		bevilges med	kr 85000000



~9.3 mio Euro

Strålskadede får dela på 30 miljoner

SVT Nyheter

Publicerad 10 november 2005 - 17:55
Uppdaterad 20 juni 2006 - 11:26

De strålskadede kvinnor som Aktuellt har berättat om i flera reportage får nu ersättning från landstingen. De får dela på sammanlagt 30 miljoner kronor.

Det handlar om 200 kvinnor som mellan åren 1962 och 1980 drabbades av svåra skador vid strålbehandling i samband med bröstcanceroperationer.


Få men höga doser

Den här unika ersättningen till de kvinnor, som fick strålbehandling med mycket stora doser hypofraktionering...

Samtidigt som de fått ersättning att döda tumörceller dödas och skadas i kroppen vävnad. Denna typ av strålbehandling leder till skador i vissa fall till allvarliga brännskador, muskel- och skelettskador.



Background DBCG HYPO



Positive results from

- Canada (2002)
- UK START Trials A & B (2008)
- Modern techniques
 - CT based
 - delineation of target & OAR
 - dose homogeneity
- Waiting lists for RT

Poor DBCG results from before 1982

Limited data from patients with

- boost
- large breasts
- modern systemic therapy
 - Taxanes, Trastuzumab
 - Letrozole



DBCG HYPO

Aim

Reintroduce moderately hypofractionated adjuvant breast radiation therapy (RT) to early node-negative breast cancer patients in a controlled and systematic way in Denmark

Hypothesis

Using 40 Gy/15 fr, 2.67 Gy /fr, for breast RT does not result in more grade 2-3 breast induration at 3 years compared with 50 Gy/25 fr

Randomization DBCG HYP0

Invasive early breast cancer or DCIS, ≥ 41 yr,
breast conservation,
pTis-pT2, pN0-pN1(mic)
any histology / ER / HER2 / grade
Boost allowed
Any breast size
Any systemic therapy

Breast implants not allowed

R


Whole breast RT 50 Gy / 25 fr

Strata:
institution,
breast size ≤ 600 cc vs > 600 cc,
chemotherapy yes/no,
boost yes/no


Whole breast RT 40 Gy / 15 fr

Endpoints


- Primary
 - grade ≥ 2 breast induration 3 years post RT
- Secondary
 - other RT-related morbidities
 - body image scale
 - patient satisfaction with therapy
 - pattern of recurrences
 - genetic risk profile for late RT-related morbidity



Statistical assumptions




Severe or moderate fibrosis



Statistical assumptions

Expected risk of **grade 2+ breast inc**
using **50 Gy/25 fr** is **estimated 10**
Accept **10%** absolute difference betw
breast RT
80% power, one-sided test, 5% sign
Number needed: **338 patients with 3**



Strategy:

"Always room for one more"

Moderate hypofractionation already routine in UK, Canada and NL

1883

Baseline data



8 Departments	Accrual
Aarhus	838
Vejle	291
Odense	254
Aalborg	167
Dresden, Gustav Carus	173
Dresden, Friedrichstadt	74
Stavanger	76
Kristiansand	10
Total	1883

Accrual: May 2009 to Mar 2014



CONSORT diagram

Randomized N=1883

Strata:
institution
boost ±
chemotherapy ±
breast volume 600 ml

**50 Gy/25 fr
N=949**

**40 Gy/15 fr
N=934**

18 withdrawn consents before
morbidity evaluation and RT

7 withdrawn consents before
morbidity evaluation and RT

6 missing baseline morbidity
evaluations

9 missing baseline morbidity
evaluations

925

918




Thus 1843 randomized patients with baseline morbidity evaluation

Patient characteristics, N=1883		50 Gy N=949	40 Gy N=934	P-value
Age (years)	Median (range)	59 (42-83)	59 (39-82)	NS
Histology	DCIS	123	125	NS
	Ductal	631	624	
	Other	195	184	
	Missing	0	1	
Tumour size	pT1a	48	66	NS
	pT1b	198	192	
	pT1c	420	411	
	pT2	160	140	
Grade (ductal)	1	217	196	NS
	2	261	255	
	3	144	167	
	NA	9	6	
Pathological nodes	pN0 (cN0)	825 (14)	835 (14)	NS
	pN1 (mic)	110	84	
	pN1	0	1	
ER status	Pos	724	691	NS
	Neg	108	122	
HER2 status	Pos	64	95	0.02
	Neg	767	710	

Max breast induration		50 Gy/25 fr	%	40 Gy/15 fr	%	P
Baseline	Grade 0	452	48.9	428	46.6	0.273
	Grade 1	289	31.2	311	33.9	
	Grade 2	158	17.1	163	17.8	
	Grade 3					
Total	1843					
Year 1	Grade 0					0.361
	Grade 1					
	Grade 2					
	Grade 3	10	1.1	11	1.2	
Total	1779	893		886		
Year 2	Grade 0	363	42.5	415	48.3	0.065
	Grade 1	379	44.4	360	41.9	
	Grade 2	100	11.7	74	8.6	
	Grade 3	12	1.4	11	1.3	
Total	1714	854		860		
Year 3	Grade 0	312	41.7	371	48.8	0.045
	Grade 1	336	44.9	302	39.7	
	Grade 2	89	11.9	75	9.9	
	Grade 3	11	1.5	12	1.6	
Total	1508	748		760		

Scores
0:none
1:slightly palpable
2:palpable
3:clearly palpable, retraction of skin and fixation

Primary endpoint: Grade 2-3 breast induration at 3 years



Induration and boost

23% of the patients had a boost

		No Boost Stratum					Boost Stratum				
		50Gy/25fr	%	40Gy/15fr	%	P	50Gy/25fr	%	40Gy/15fr	%	P
Baseline	Grade 0	322	45.2	306	43.5	0.388	130	61.3	122	57.0	0.743
	Grade 1	227	31.8	242	34.4		62	29.2	69	32.2	
	Grade 2	141	19.8	142	20.2		17	8.0	21	9.8	
	Grade 3	23	3.2	14	2.0		3	1.4	2	0.9	
Total	1843	713		704			212		214		
Year 3	Grade 0	236	41.2	290	49.9	0.023	76	43.4	81	45.3	0.765
	Grade 1	261	45.5	222	38.2		75	42.9	80	44.7	
	Grade 2	68	11.9	59	10.2		21	12.0	16	8.9	
	Grade 3	8	1.4	10	1.7		3	1.7	2	1.1	
Total	1508	573		581			175		179		

Actuarial 3 year risk of grade 2-3 breast induration irrespective of fractionation using year 1 as baseline (boost no/yes)
 HR 1.10 (95% CI 0.79-1.52), p=0.59

FROM E



Induration and chemotherapy

36% of the patients had taxane-based chemotherapy

		No Chemotherapy Stratum					Chemotherapy Stratum				
		50Gy/25fr	%	40Gy/15fr	%	P	50Gy/25fr	%	40Gy/15fr	%	P
Baseline	Grade 0	231	39.3	210	35.8	0.135	221	65.6	218	65.9	0.875
	Grade 1	189	32.1	218	37.1		100	29.7	93	28.1	
	Grade 2	143	24.3	144	24.5		15	4.5	19	5.7	
	Grade 3	25	4.3	15	2.6		1	0.3	1	0.3	
Total	1843	588		587		337		331			
Year 3	Grade 0	209	43.2	235	49.4	0.266	103	39.0	136	47.9	0.07
	Grade 1	212	43.8	183	38.4		124	47.0	119	41.9	
	Grade 2	55	11.4	52	10.9		34	12.9	23	8.1	
	Grade 3	8	2.6	6	1.3		3	1.01	6	2.1	
Total	1508	484		476		264		284			

**Actuarial 3 year risk of grade 2-3 breast induration irrespective of fractionation using year 1 as baseline (chemo no/yes)
HR 1.06 (95% CI 0.79-1.42), p=0.70**

FROM E

ASSOC



Induration and breast volume

Median size of CTVp_breast 644 ml (50 Gy) and 635 ml (40 Gy)

		Small breasts Stratum (≤ 600 ml CTVp_breast)					Large breasts Stratum (> 600 ml CTVp_breast)				
		50Gy/25fr	%	40Gy/15fr	%	P	50Gy/25fr	%	40Gy/15fr	%	P
Baseline	Grade 0	213	48.6	212	49.0	0.179	239	49.1	216	44.5	0.542
	Grade 1	134	30.6	146	33.7		155	31.8	165	34.0	
	Grade 2	74	16.9	68	15.7		84	17.2	95	19.6	
	Grade 3	17	3.9	7	1.6		9	1.8	9	1.9	
Total	1843	438		433			487		485		
Year 3	Grade 0	173	49.6	200	56.3	0.163	139	34.8	171	42.2	0.190
	Grade 1	135	38.7	124	34.9		201	50.4	178	44.0	
	Grade 2	38	10.9	26	7.3		51	12.8	49	12.1	
	Grade 3	3	0.9	5	1.4		8	2.0	7	1.7	
Total	1508	349		355			399		405		

Actuarial 3 year risk of grade 2-3 breast induration irrespective of fractionation using year 1 as baseline (small/large)

HR 1.56 (95% CI 1.16-2.09), p=0.003


FROM

ESCO




Breast volume and dose distribution

D_{max} in CTV



A little overdosage More overdosage



Significantly more inhomogeneous dose distribution in large breasts, $P < 0.0001$



Cox proportional hazards analysis using breast induration grades 2-3 as endpoint

VARIABLE	P value	RR	95% CI
UNIVARIATE			
Hypo (40 Gy vs 50 Gy)	0.74	0.95	(0.72-1.27)
<i>Breast size (S vs L)</i>	<i>0.003</i>	<i>1.56</i>	<i>(1.16-2.09)</i>
Chemotherapy (no vs yes)	0.70	1.06	(0.79-1.42)
Boost (no vs yes)	0.59	1.10	(0.79-1.52)
MULTIVARIATE			
Hypo (40 Gy vs 50 Gy)	0.74	0.95	(0.72-1.27)
<i>Breast size (S vs L)</i>	<i>0.003</i>	<i>1.56</i>	<i>(1.16-2.09)</i>
Chemotherapy (yes vs no)	NS		
Boost (yes vs no)	NS		



Recurrences and new events

	50 Gy / 25 fr	40 Gy / 15 fr
Local recurrence	7	7
Loco-reg recurrence	10	7
Contralateral DCIS/BC	2/12	3/7
Distant recurrence	14	16
Other malignant disease	18	19

		P	HR	95% CI
Local recurrence	40 vs 50	0.88	0.92	0.33-2.55
Loco-reg recurrence	40 vs 50	0.57	1.31	0.51-3.32
Distant recurrence	40 vs 50	0.65	0.81	0.32-1.97
All failures	40 vs 50	0.94	1.03	0.53-1.97



Conclusion

External beam forward planned IMRT whole breast irradiation based on 40 Gy/15 fr is feasible

- Few side effects at 3 yr with no difference in breast induration comparing 40 Gy/15 fr with 50 Gy/25 fr
- Large breast volume is an independent risk factor for developing breast induration 3 years post RT
- Use of boost, chemotherapy or hypofractionation have no impact on 3-year breast induration
- Few recurrences, and not related to fractionation
- Moderately hypofractionated whole breast RT has become the new DBCG standard to all patients treated with breast only RT since 2014



Acknowledgements

PATIENTS, investigators, physicists, radiographers, nurses and research support staff at all 8 participating centres

Sponsored by the Danish Cancer Society, CIRRO (Centre for Interventional Research in Radiation Oncology) and Breast Friends

